实用肝脏病杂志 ›› 2018, Vol. 21 ›› Issue (3): 401-404.doi: 10.3969/j.issn.1672-5069.2018.03.021

• 丙型肝炎 • 上一篇    下一篇

慢性丙型肝炎外周血miR-1273g-3p水平变化及其诊断肝纤维化分期的效能分析*

王婧婧, 张瑜, 董娜, 韩振坤, 翟景明   

  1. 471003 河南省洛阳市 河南科技大学第一附属医院检验科(王婧婧); 消化内科(张瑜); 病理科(董娜); 放疗科(韩振坤); 肝胆外科(翟景明)
  • 收稿日期:2018-01-09 出版日期:2018-05-10 发布日期:2018-05-25
  • 作者简介:王婧婧,女,38岁,医学硕士,主治医师。E-mail:rld2549@163.com
  • 基金资助:
    *项目基金:河南省科技计划项目(编号:152102310406)

Efficacy of serum miR-1273g-3p levels in diagnosis of liver fibrosis in patients with chronic hepatitis C

Wang Jingjing, Zhang Yu, Dong Na, et al   

  1. Clinical Laboratory,First Affiliated Hospital,Henan Science & Technology University,Luoyang 471003,Henan Province,China
  • Received:2018-01-09 Online:2018-05-10 Published:2018-05-25

摘要: 目的 探讨检测血清miR-1273g-3p水平诊断慢性丙型肝炎(CHC)患者肝纤维化分期的效能。方法 我院诊治的57例CHC患者和同期入选的21例经体检显示为正常的健康人,采用实时荧光定量PCR法检测血清miR-1273g-3p水平。CHC患者接受长效干扰素α2b联合利巴韦林标准疗法治疗12 m,并接受肝穿刺活检行组织病理学检查。结果 13例肝组织呈F0期患者血清miR-1273g-3p相对水平为(1.02±0.3),20例F1-2期患者为(1.68±0.26),24例F3-4期患者为(4.21±0.42),存在肝纤维化的CHC患者血清miR-1273g-3p相对水平显著高于健康人【(1.03±0.2),P<0.05】;在抗病毒治疗12 m末,CHC F0期、F1-2期和F3-4期患者血清miR-1273g-3p相对水平依次变化为(1.03±0.4)、(1.43±0.22)和(3.97±0.2),均显著低于治疗前(P<0.05);在治疗前,分别以血清miR-1273g-3p水平>1.68和血清miR-1273g-3p水平>4.20为截断点诊断存在肝纤维化和显著肝纤维化,其ROC曲线下面积(AUC)分别为0.830,95%CI为0.714~0.973,诊断的灵敏度为72.2%,特异度为86.4%,和0.864,95%CI为0.701~0.976,诊断的灵敏度为83.6%,特异度为78.4%;在治疗后,经肝组织病理学检查发现CHC患者 F0期、F1期、F2期、F3、F4期依次为15例、9例、14例、11例、8例,血清miR-1273g-3p水平诊断存在肝纤维化和显著肝纤维化的效能仍然较好。结论 血清miR-1273g-3p水平随着CHC患者肝纤维化进展而逐渐升高,在抗病毒治疗后,随着肝纤维化的缓解而降低,因而具有一定的判断肝纤维化程度的效能,值得进一步研究。

关键词: 慢性丙型肝炎, 肝纤维化, 血清miR-1273g-3p, 诊断

Abstract: Objective T o explore the efficacy of serum miR-1273g-3p levels in diagnosis of liver fibrosis in patients with chronic hepatitis C(CHC). Methods 57 patients with CHC and 21 healthy persons were recruited in our hospital,and serum miR-1273g-3p were detected by real-time polymerase chain reaction. The patients with CHC received standardized peg-interferon-α2b and ribavirin therapy for 12 months,and received liver biopsies before and after the regimen. Results Serum miR-1273g-3p levels were(1.02±0.3) in 13 CHC patients with liver fibrosis 0(F0),(1.68±0.26) in 20 with F 1-2,and(4.21±0.42) in 24 with F 3-4,respectively,which suggested serum miR-1273g-3p levels in patients with liver fibrosis were much higher than 【(1.03±0.2),P<0.05】 in healthy persons or in patients without;at the end of the regimen,serum miR-1273g-3p levels in patients with CHC F0,F1-2 and F3-4 were(1.03±0.4),(1.43±0.22) and (3.97±0.2),respectively,much lower than those before anti-viral treatment (P<0.05);the AUC of serum miR-1273g-3p levels in diagnosing liver fibrosis and significant liver fibrosis were 0.830,95%CI为0.714~0.973 (sensitivity 72.2% and specificity 86.4%),and were 0.864,95%CI为0.701~0.976 (sensitivity 83.6% and specificity 78.4%,as the cut-off-value were >1.68 and >4.20,respectively;at discontinuation of the regimen,the liver histological examination showed that the liver fibrosis was F0 in 15,F1 in 9,F2 in 14,F3 in 11 and F4 in 8. Conclusion s Serum miR-1273g-3p levels might be used to diagnose liver fibrosis in patients with CHC,which warrants further investigation.

Key words: Hepatitis C, miR-1273g-3p, Liver fibrosis, Diagnosis